Lv6
1620 积分 2022-10-25 加入
Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies
9天前
已完结
Discovery of a High-Potency Balanced GLP-1/GIP Dual Agonist by Molecular Dynamics Evolution
11天前
已完结
Sirolimus Pharmacokinetics Variability Points to the Relevance of Therapeutic Drug Monitoring in Pediatric Oncology
17天前
已完结
Model-Informed individualized dosage regimen of sirolimus in pediatric patients with intractable lymphatic malformations
18天前
已完结
Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies
18天前
已完结
Predictors of sirolimus pharmacokinetic variability identified using a nonlinear mixed effects approach: a systematic review
18天前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
19天前
已完结
EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates antitumor activity in metastatic castration-resistant prostate cancer
19天前
已完结
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial
19天前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
19天前
已完结
皖公网安备34019202002308
